Clinical Trials Logo

Clinical Trial Summary

Facioscapulohumeral Muscular Dystrophy (FSHD) is one of the most common forms of muscular dystrophy, characterized by pronounced skeletal weakness and with a broad spectrum of diseases. It is a hereditary disease seen in 3-5/100,000 of society, usually starting with weakness in the facial and shoulder muscles and progressing to the trunk, pelvis and leg muscles, giving symptoms in the twenties. In FSHD, which shows slow progression and can lead to loss of ambulation ability in about 20% of patients, patients may have difficulty performing activities above shoulder level with the influence of the periscapular area. The goal of FSHD treatment is to improve muscle strength and/or function. Treatments include medical, conservative and surgical methods. The aim of surgical methods is to improve shoulder function and prevent pain caused by the movements of the scapula. The publications on physiotherapy interventions and aerobic exercise are available as conservative treatment. In patients diagnosed with FSHD, conservative treatment is frequently used to improve muscle strength, regulate function and improve the quality of life of patients. Patients with FSHD use their affected upper extremities asymmetrically, which leads to the development of restrictive compensation mechanisms in the development of symmetrical postural control. Postural control deficits may occur due to limited use of the affected scapula in individuals with FSHD. Accordingly, in cases with FSHD, there is the use of atypical movements for balance and mobility. It is not yet known whether people with FSHD really have poorer dynamic stability during self-initiated whole-body movements such as walking, and at what stage of the disease these difficulties arise. Accordingly, the aim of this study was to examine the effects of rehabilitation approaches applied to the upper limb on upper limb function, balance and walking in patients with FSHD. H1: Within the group of patients with FSHD patients underwent surgery arthrodesis surgery scapulothoracic applied to pre-treatment with the parameters of the rehabilitation program for the evaluation of upper limb functionality after applying the upper extremities, postural control and gait parameters examined, there is statistical difference between the groups.


Clinical Trial Description

Voluntary participants who have been diagnosed with FSHD and agreed to voluntary health subjects will be included in the study. Signed voluntary consent will be obtained from participants. Participants will be divided into tree groups. One group will include patients who have undergone scapulothoracic arthrodesis surgery, while the other group will include patients who have not undergone surgery and control group will include participants who have agree to participate the study. A progressive rehabilitation program for the upper extremities will be applied to patients in a group of individuals who have undergone and have not undergone surgery. Both groups will undergo some outcome measures to assess their upper extremity function, balance and walking. ;


Study Design


Related Conditions & MeSH terms

  • Facioscapulohumeral Muscular Dystrophy
  • Muscular Dystrophies
  • Muscular Dystrophy, Facioscapulohumeral

NCT number NCT05178706
Study type Observational
Source Istanbul University - Cerrahpasa (IUC)
Contact
Status Completed
Phase
Start date February 22, 2022
Completion date June 10, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT00082108 - Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Completed NCT02579239 - Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) Phase 1/Phase 2
Terminated NCT02927080 - Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) Phase 2
Completed NCT02625662 - Facioscapulohumeral Dystrophy in Children
Recruiting NCT04001582 - The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry
Terminated NCT03943290 - Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX) Phase 2
Completed NCT01596803 - Effects Antioxidants Supplementation on Muscular Function Patients Facioscapulohumeral Dystrophy (FSHD) N/A
Active, not recruiting NCT03458832 - Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
Completed NCT02766985 - Rasch-analysis of Clinical Severity in FSHD
Active, not recruiting NCT01671865 - Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy
Completed NCT02413190 - Bone Health in Facioscapulohumeral Muscular Dystrophy
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Completed NCT01437345 - A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD N/A
Completed NCT02836418 - Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD) Phase 1/Phase 2
Not yet recruiting NCT06086548 - Unraveling Metabolic Involvement in Facioscapulohumeral Dystrophy Through Metabolomics
Completed NCT00821548 - Electrostimulation of Shoulder Girdle and Quadriceps Muscles in Facioscapulohumeral Muscular Dystrophy Patients N/A
Completed NCT00104078 - Study Evaluating MYO-029 in Adult Muscular Dystrophy Phase 1/Phase 2
Recruiting NCT05019625 - Biomarker Development for Muscular Dystrophies
Completed NCT03123913 - Study of Testosterone and rHGH in FSHD Phase 1
Completed NCT04267354 - Arm Cycling in Facioscapulohumeral Dystrophy (FSHD) Patients N/A